Back to Search Start Over

Rykindo Approved for Schizophrenia, Bipolar Disorder

Authors :
Park, Brian
Source :
Clinical Advisor. January 19, 2023
Publication Year :
2023

Abstract

The Food and Drug Administration (FDA) has approved Rykindo[sup.®] (risperidone extended-release injectable suspension for intramuscular [IM] use) for the treatment of schizophrenia in adults, and as monotherapy or as adjunctive [...]

Subjects

Subjects :
United States. Food and Drug Administration
Bipolar disorder -- Drug therapy
Schizophrenia -- Drug therapy
Drug approval
Health

Details

Language :
English
ISSN :
15247317
Database :
Gale General OneFile
Journal :
Clinical Advisor
Publication Type :
Periodical
Accession number :
edsgcl.733774168

Tools

Authors Abstract Subjects Details